Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $298.9 million.

  • IDEAYA Biosciences' Cash & Equivalents fell 2532.11% to $298.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.9 million, marking a year-over-year decrease of 2532.11%. This contributed to the annual value of $84.4 million for FY2024, which is 4626.22% down from last year.
  • Per IDEAYA Biosciences' latest filing, its Cash & Equivalents stood at $298.9 million for Q3 2025, which was down 2532.11% from $114.6 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Cash & Equivalents registered a high of $400.3 million during Q3 2024, and its lowest value of $49.1 million during Q2 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $108.3 million (2024), whereas its average is $131.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 28562.97% in 2021, then crashed by 5956.84% in 2022.
  • IDEAYA Biosciences' Cash & Equivalents (Quarter) stood at $92.0 million in 2021, then fell by 25.44% to $68.6 million in 2022, then surged by 128.78% to $157.0 million in 2023, then plummeted by 46.26% to $84.4 million in 2024, then soared by 254.27% to $298.9 million in 2025.
  • Its last three reported values are $298.9 million in Q3 2025, $114.6 million for Q2 2025, and $130.0 million during Q1 2025.